About gossamer bio inc - GOSS
Gossamer Bio, Inc. engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions. The company was founded by Faheem Hasnain and Sheila Gujrathi on October 26, 2015 and is headquartered in San Diego, CA.
GOSS At a Glance
Gossamer Bio, Inc.
3115 Merryfield Row
San Diego, California 92121
| Phone | 1-858-684-1300 | Revenue | 48.47M | |
| Industry | Pharmaceuticals: Major | Net Income | -170,370,000.00 | |
| Sector | Health Technology | Employees | 162 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
GOSS Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 14.615 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -4.773 |
| Enterprise Value to Sales | 15.976 |
| Total Debt to Enterprise Value | 0.262 |
GOSS Efficiency
| Revenue/Employee | 299,203.704 |
| Income Per Employee | -1,051,666.667 |
| Receivables Turnover | 3.869 |
| Total Asset Turnover | 0.199 |
GOSS Liquidity
| Current Ratio | 2.643 |
| Quick Ratio | 2.643 |
| Cash Ratio | 2.159 |
GOSS Profitability
| Gross Margin | 97.933 |
| Operating Margin | -336.806 |
| Pretax Margin | -351.67 |
| Net Margin | -351.489 |
| Return on Assets | -69.89 |
| Return on Equity | N/A |
| Return on Total Capital | -212.575 |
| Return on Invested Capital | -109.696 |
GOSS Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 253.17 |
| Total Debt to Total Assets | 117.798 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 252.00 |